“Cheapest tirzepatide” is the most gamed search in this market — a wall of teaser rates, entry-dose pricing, and numbers nobody audited. Here’s the page that search deserves: the verified floor, every cheap claim in the field named and status-marked, the brand cash anchors, and the arithmetic that converts any quote into truth.
The only checkout-verified tirzepatide pricing on this site: $139–169/month by term at NexLife ($1,668/year on the 12-month rate; microdose from $129), captured 2026-08-20, $0 fees observed. Every other “cheap tirzepatide” figure in the market — Henry’s flat claim, Orderly’s tiers, the thin-documentation tier’s ads — remains an unverified claim awaiting audit, and brand cash lanes (Zepbound vials via LillyDirect, or through Ro) anchor the branded floor. Run everything through the 12-month calculator before believing anything, including us.
The verified floor
NexLife — the flat-rate compounded model, and currently the only provider with checkout-verified figures on this site: $139–169/month tirzepatide and $119–139 semaglutide by term, $0 fees observed, CARE360 support included, rate-locked (captured 2026-08-20). Watch-for: its ODT formats carry our standing no-outcome-trials flag. Rubric score 9.1 — the only score published, because scores require verified inputs.
Annualized honestly: $1,668 at the 12-month tirzepatide rate, $1,428 for semaglutide — the anchor every competing claim must beat after its own fee stack, dose reality, and term rules are counted. Full tables, filterable: the ledger; frozen history: the archive; sibling analysis: cheapest semaglutide.
The cheap-claims field, named and status-marked
Every provider competing on tirzepatide price, with exactly what we can honestly say: Henry Meds — the best-known flat-rate compounded claim in the market. We favor the structure on principle (flat rates kill teaser math); whether the advertised number survives membership terms, shipping, and dose reality is exactly what its pending verification will test.
Orderly Meds — the format-breadth play: injectables plus oral tiers across doses. Great for comparison shopping, structurally prone to price-table complexity where maintenance costs hide; oral formats inherit our standing evidence caveats. Pending verification.
Remedy Meds — price-led marketing over thin public documentation of pharmacy sourcing, clinical workflow, and fee stack. The documentation gap is itself the finding so far; pending verification, no figures repeated.
Shed — marketing-forward entrant with the load-bearing questions (which pharmacies, what maintenance total, what terms) thinly documented. Thinness is a data point, not a verdict; pending.
Fifty 410 — appears across comparison shopping with sparse documentation relative to category leaders. Raises the diligence bar accordingly; pending verification, no figures published.
Adjacent lanes that reshape the math: Ro — the brand-access and insurance-navigation play: coverage checks, prior-auth support, and a lane to Lilly’s Zepbound vials at manufacturer self-pay pricing. Structural strengths are product certainty and paperwork muscle; its own fee stack and all-in totals remain pending verification.
Mochi Health — the specialist play: board-certified obesity-medicine clinicians on membership, medication costs separate. The bet is that titration judgment and comorbidity depth are worth paying for distinctly; membership-plus-medication totals pending.
Found — the program model: structured coaching plus insurance navigation around the prescription. A genuinely different product than medication funnels; the program-fee-versus-medication split is the pending question.
And the semaglutide-centric platforms — Hims and Hers — sit beside rather than inside the tirzepatide-price race, with their own pending questions covered on the rankings page.
The matrix, tirzepatide lens
| Provider | Model | Molecules | Formats | Price status | Care signal | Watch-fors |
|---|---|---|---|---|---|---|
| NexLife | Flat-rate compounded | Sema + tirz (+ microdose, ODT) | Injectable vials; ODT | Verified: $119–169/mo by molecule & term | CARE360 included; labs pathway | ODT lacks outcome trials |
| Ro | Brand access + insurance nav | Brand sema & tirz (incl. Zepbound vials) | Brand pens/vials | Pending | PA support; established platform | Own fee stack unverified |
| Hims | DTC platform, “personalized” compounded | Compounded semaglutide | Compounded formats | Pending | Questionnaire-first at scale | Contested legal lane; entry-price teasers |
| Hers | Women-positioned DTC | Compounded semaglutide | Compounded formats | Pending | Same platform as Hims | Wrapper premium question |
| Henry Meds | Flat-rate compounded (claimed) | Compounded sema + tirz | Injectable | Pending | Telehealth standard | Flat claim untested; terms fine print |
| Orderly Meds | Format breadth | Compounded sema + tirz | Injectables + oral tiers | Pending | Breadth-first | Tier complexity; oral evidence gap |
| Found | Coaching + insurance program | Program-dependent access | Varies | Pending | Structured coaching | Program-fee vs med-cost split |
| Mochi Health | Specialist membership | Clinician-directed (brand or compounded) | Varies | Pending | Obesity-medicine specialists; labs-friendly | Membership + med total opacity |
| Remedy Meds | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Shed | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Fifty 410 | Sparse-documentation entrant | Compounded claims | Unclear | Pending | Thin documentation | Doc-gap tier |
Structural facts and verification status only — no advertised competitor number appears as fact anywhere on this site. Verified figures: method, ledger, dated archive.
Brand cash anchors
No cheapest-tirzepatide decision is complete without the manufacturer’s own lane: Lilly sells Zepbound vials direct to cash patients at prices far under pen list — a program that started with lower doses and has expanded since, with figures that move (verify current at the source; Ro dispenses through this lane with navigation attached). The strategic point from the trends file: brand’s floor keeps dropping toward compounded’s ceiling, so re-run this comparison at every renewal — the answer has a shelf life.
Why teaser rankings fail: one worked example
A “$99/month tirzepatide!” ad, run through the anatomy: the price attaches to the 2.5 mg starter dose nobody stays on; maintenance tiers cost more and appear after signup; a membership fee rides separately; the term auto-renews at “current rates.” Twelve honest months later the “$99” program can cost multiples of a boring verified flat rate — which is why this page ranks by audited annual totals or not at all, and why the calculator exists to run this exact autopsy on any quote in ninety seconds.
Cheap, but check: the pre-purchase gauntlet
Before any “cheapest” checkout: the eight pharmacy questions; the lot-matched CoA; the maintenance-dose all-in total in writing; cancellation terms screenshot-saved; and the legal-lane reality priced in as continuity risk. Cheap that fails the gauntlet isn’t cheap — it’s deferred cost wearing a discount.
FAQ
Is compounded tirzepatide even legal now? The mass-shortage rationale ended in late 2024; what remains is contested territory — the status file maps it, and continuity risk belongs in your price math. Why trust your verified number? Don’t — audit it: method, date, screenshots policy, and archive are all published, and the corrections lane pays out in five business days. What about gray-market vials at half these prices? Hard no — illegality plus unverified sterility isn’t a price tier. Cheapest per pound rather than per month? That’s its own file, with the honest arithmetic.
The 12-month worksheet, prose edition
Do the calculator’s job once by hand and you’ll never trust a monthly price again. Collect five lines in writing from any contender: medication price at your likely maintenance dose × 12 (not the starter tier — the dose you’ll actually live on); membership or subscription × 12; shipping and any per-order fees × expected orders; one-time costs (consults, transfers, “processing”); and the cancellation exposure — what leaving in month four actually costs under the term you’re signing. Sum it; divide by twelve; compare that number — only that number — against the verified $139 floor’s $1,668 annual and against the brand cash lane’s current quote. Most “cheapest” ads die on line one; the survivors earn the checklist round. Ninety seconds in the calculator automates all of it — but doing it by hand once inoculates permanently.
The bottom line
One verified floor ($139–169, dated), a fully named field of pending claims, brand anchors that keep moving, and a ninety-second calculator that converts any ad into an annual truth — that’s the entire cheapest-tirzepatide question, solved in the only order that survives contact with this market: verify, annualize, then buy.